Ebrotidine

H2-receptor antagonist,competitive CAS# 100981-43-9

Ebrotidine

Catalog No. BCC1542----Order now to get a substantial discount!

Product Name & Size Price Stock
Ebrotidine: 5mg $299 In Stock
Ebrotidine: 10mg Please Inquire In Stock
Ebrotidine: 20mg Please Inquire Please Inquire
Ebrotidine: 50mg Please Inquire Please Inquire
Ebrotidine: 100mg Please Inquire Please Inquire
Ebrotidine: 200mg Please Inquire Please Inquire
Ebrotidine: 500mg Please Inquire Please Inquire
Ebrotidine: 1000mg Please Inquire Please Inquire
Related Products
  • Metiamide

    Catalog No.:BCC1742
    CAS No.:34839-70-8
  • Famotidine

    Catalog No.:BCC4529
    CAS No.:76824-35-6

Quality Control of Ebrotidine

Number of papers citing our products

Chemical structure

Ebrotidine

3D structure

Chemical Properties of Ebrotidine

Cas No. 100981-43-9 SDF Download SDF
PubChem ID 65869 Appearance Powder
Formula C14H17BrN6O2S3 M.Wt 477.42
Type of Compound N/A Storage Desiccate at -20°C
Synonyms FI3542
Solubility DMSO : 100 mg/mL (209.46 mM; Need ultrasonic)
Chemical Name N-(4-bromophenyl)sulfonyl-N'-[2-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]ethyl]methanimidamide
SMILES C1=CC(=CC=C1S(=O)(=O)NC=NCCSCC2=CSC(=N2)N=C(N)N)Br
Standard InChIKey ZQHFZHPUZXNPMF-UHFFFAOYSA-N
Standard InChI InChI=1S/C14H17BrN6O2S3/c15-10-1-3-12(4-2-10)26(22,23)19-9-18-5-6-24-7-11-8-25-14(20-11)21-13(16)17/h1-4,8-9H,5-7H2,(H,18,19)(H4,16,17,20,21)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Ebrotidine

DescriptionEbrotidine(FI 3542) is a competitive H2-receptor antagonist (Ki= 127.5 nM) with a potent antisecretory activity and evidenced gastroprotection. IC50 Value: 127.5 nM (Ki)[1]; 0.21mg/kg (ED50, histamine- stimulated acid secretion) [2] Target: H2 receptor in vitro: Ebrotidine displaced 3H-thiotidine specific binding to histamine H2-receptors (Ki: 127.5 nmol/l), showing a higher affinity (p < 0.05) than ranitidine (Ki: 190.0 nmol/l) and cimetidine (Ki: 246.1 nmol/l) [1]. in vivo: Following intravenous administration to rats, ebrotidine inhibited histamine- and pentagastrin-stimulated acid secretion in a dose-dependent manner, ED50 being 0.21 and 0.44 mg/kg, respectively [2]. The mean number of gastric erosions seen at endoscopy after treatment with ebrotidine plus ASA (2.0 +/- 0.3) was significantly lower than that after placebo plus ASA (3.7 +/- 0.2). This reduction in lesion core by ebrotidine was accompanied by a significant increase in gastric blood flow (by 15% in corpus and 26% in antrum), by a rise in transmucosal potential difference (by 12%), and by a decrease of mucosal microbleeding [3]. Results of macroscopic assessment revealed that ebrotidine at doses of 50mg and higher/kg body weight effectively prevented mucosal injury, and that the maximal protective effect was achieved by 1h. Physicochemical analysis established that ebrotidine evoked 30% increase in mucus gel dimension, and showed 20% increase in phospholipids, and the content of sulfo- (18%) and sialomucins (21%) [4].

References:
[1]. Agut J, Sánchez JC, Sacristán A, Action of ebrotidine, ranitidine and cimetidine on the specific binding to histamine H1- and H2-receptors. Arzneimittelforschung. 1997 Apr;47(4A):447-9. [2]. Palop D, Agut J, Márquez M, Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat. Arzneimittelforschung. 1997 Apr;47(4A):439-46. [3]. Konturek SJ, Kwiecien N, Sito E, Effects of ebrotidine on aspirin-induced gastric mucosal damage and blood flow in humans. Scand J Gastroenterol. 1993 Dec;28(12):1047-50. [4]. Piotrowski J, Yamaki K, Morita M, Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity. Biochem Int. 1992 Mar;26(4):659-67.

Protocol

Cell experiment: [1]

Cell lines

Helicobacter. pylori

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reacting condition

MIC: 75 micrograms/ml, 5 days

Applications

Ebrotidine gave a mean MIC value of 75 micrograms/ml. Ebrotidine at 100 micrograms/ml enhanced the activity of the antimicrobials studied as follows: erythromycin 3 times, tetracycline 1.1 times, amoxicillin 3 times, metronidazole-sensitive strains 9 times and clarithromycin 5 times.

Animal experiment: [2]

Animal models

Sprague-Dawley rats with chronic gastric ulcers

Dosage form

Intragastric route100 mg/kg, twice daily for 14 days

Application

Treatment with ebrotidine resulted in an accelerated ulcer healing. A 40% decrease in ulcer area was observed by the third day and a 71% decrease by the fifth day; the ulcers were essentially healed by the seventh day.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Palacin C, Tarrago C, Sacristan A, et al. In vitro anti-Helicobacter pylori activity of ebrotidine. Arzneimittel-Forschung, 1997, 47(4A): 471-474.

[2] Slomiany B L, Piotrowski J, Slomiany A. Cell cycle progression during gastric ulcer healing by ebrotidine and sucralfate. General Pharmacology: The Vascular System, 1997, 29(3): 367-370.

Ebrotidine Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Ebrotidine Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Ebrotidine

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.0946 mL 10.473 mL 20.9459 mL 41.8918 mL 52.3648 mL
5 mM 0.4189 mL 2.0946 mL 4.1892 mL 8.3784 mL 10.473 mL
10 mM 0.2095 mL 1.0473 mL 2.0946 mL 4.1892 mL 5.2365 mL
50 mM 0.0419 mL 0.2095 mL 0.4189 mL 0.8378 mL 1.0473 mL
100 mM 0.0209 mL 0.1047 mL 0.2095 mL 0.4189 mL 0.5236 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Ebrotidine

Ebrotidine is a selective antagonist of histamine H2-receptor with Ki value of 127.5 nM [1].

Ebrotidine inhibited the secretion of gastric acid through competing with histamine for the combination with H2-receptor. It was found to have gastroprotective effect via abating the hyperplastic effects in gastric enteroendocrine cells and interfering the proteolytic and lipolytic activities and the urease of Helicobacter pylori. Besides that, ebrotidine promoted the proliferation of the epithelial cells and alleviated the effects brought by stress, ethanol and aspirin. Unlike other H2 inhibitors, ebrotidine showed no carcinogenic risk enterochromaffin-like cells of mice [1 and 2].

Ebrotidine showed about 10-fold higher anti-secretory effects than cimetidine. Its affinity for H2-receptor was 1.5- and 2-fold higher than that of ranitidine and cimetidine, respectively. In the in vitro assays, ebrotidine promoted the phospholipid secretion of gastric mucosa and maintained the calcium balance of mucosal cells through suppressing EGF-induced phosphorylation of calcium channel proteins. Ebrotidine exerted anti- Helicobacter pylori potency with MIC90 value of 256 mg/L. It inhibited 57% of the proteolytic activity and 93% of the lipolytic activity of the bacteria at concentrations of 35 and 60 mg/L, respectively. In addition, ebrotidine displayed inhibition effects on the urease at a low concentration of 2.1 μM by 77% [1].

The administration of 1 to 100 mg/kg ebrotidine dose-dependently inhibited gastric acid secretion in rats. The effects could last for about 8 hours when the dose was 100 mg/kg. Ebrotidine was also found to have the ability of helping healing ulcer [1].

References:
[1].  Patel S S, Wilde M I. Ebrotidine. Drugs, 1996, 51(6): 974-80; discussion 981.
[2].  Romero A, Gómez F, Villamayor F, et al. Study of the population of enterochromaffin-like cells in mouse gastric mucosa after long-term treatment with ebrotidine. Toxicologic pathology, 1996, 24(2): 160-165.

Featured Products
New Products
 

References on Ebrotidine

Determination of ebrotidine metabolites in overlapping peaks from capillary zone electrophoresis using chemometric methods.[Pubmed:11197182]

Electrophoresis. 2001 Jan;22(1):71-6.

This paper illustrates the possibilities of chemometric methods in the resolution and quantification of various compounds in overlapping peaks from capillary electrophoresis. Ebrotidine and most of its metabolites were efficiently separated by capillary zone electrophoresis (CZE) in a fused-silica capillary. However, the procedure was not suitable for the physical separation of the three less ionizable metabolites, which comigrated and overlapped with the electroosmotic flow signal. Multivariate curve resolution based on an alternating least squares procedure was used for their mathematical resolution. For such a purpose, data obtained in the CZE system with a diode array detector, which consisted of UV spectra registered over time, were analyzed. The Ebrotidine metabolites were successfully resolved and quantified in synthetic mixtures and urine samples.

Determination of ebrotidine and its metabolites by capillary electrophoresis with UV and mass spectrometry detection.[Pubmed:10949494]

J Chromatogr A. 2000 Aug 4;888(1-2):281-92.

This study describes the application of capillary electrophoresis (CE) to the analysis of Ebrotidine and its metabolites as an alternative analytical technique to liquid chromatography. Comparison between UV-diode array spectroscopy and mass spectrometry (MS) using an ion-trap system with electrospray ionization as detection systems has been performed. The quality parameters of the UV detection method were established, obtaining linear calibration curves over the range studied (8-200 mg ml(-1)), limits of detection between 3.4 and 4.3 microg ml(-1), and run-to-run and day-to-day precision lower than 14%. For these compounds the protonated species [M+H]+ and, in some cases, sodium adducts were observed in the MS spectra. Using MS coupled to CE, limits of detection were between 0.5 and 2.6 microg ml(-1).

Description

Ebrotidine(FI 3542) is a competitive H2-receptor antagonist (Ki= 127.5 nM) with a potent antisecretory activity and evidenced gastroprotection.

Keywords:

Ebrotidine,100981-43-9,FI3542,Natural Products,Histamine, buy Ebrotidine , Ebrotidine supplier , purchase Ebrotidine , Ebrotidine cost , Ebrotidine manufacturer , order Ebrotidine , high purity Ebrotidine

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: